Efficacy of Nicotinamide on Retinal Ganglion Cell Functions in Glaucoma Patients
Efficacy of Nicotinamide on Retinal Ganglion Cell Functions in Glaucoma Patients : Clinical Trial, Cross-over Design, Double-blind, Placebo-control, Randomized, Single-center Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Seungsoo Rho, MD, PhD
- Phone Number: 82-10-9260-3173
- Email: harryrho@gmail.com
Study Locations
-
-
Bundang-gu
-
Seongnam, Bundang-gu, Korea, Republic of, 13497
- Recruiting
- CHA University Bundang Medical Center
-
Contact:
- Seungsoo Rho, MD, PhD
- Phone Number: +82-10-9260-3173
- Email: harryrho@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult(Male or Female) over 19 years who were diagnosed with glaucoma.
- In the case of participants receiving glaucoma treatment drugs, the investigator judges that the intraocular pressure remains constant for at least 1 year.
- Intraocular pressure (IOP) >/= 8mmHg and < 18mmHg in each eye using Goldmann applanation tonometry prior to the screening visit
- Adult participants diagnosed and treated for early-moderate glaucoma (VF mean deviation(MD) ≥-12 dB)
- Have performed a reliable visual field in the last year, with <33% fixation losses, false positives and false negatives.
- Written consent voluntarily to participate in this clinical trial.
Exclusion Criteria:
- Patients with congenital glaucoma and secondary glaucoma caused by steroid drugs, etc.
- BCVA (best-corrected visual acuity) Snellen equivalent of Snellen 20/80(logMar 0.25) or less.
- Patients who have medical history of ocular inflammation
- Patients with any ocular/systemic conditions that may affect electroretinogram parameter, or with visual field defects(Ischemic optic neuropathy, Proliferative diabetic retinopathy, Macular degeneration etc.)
- Patients who have plans to intraocular surgery within the clinical trial period.
- Patients with a history of significant ocular trauma within 6 months prior to the screening visit
- Pregnant or lactating women.
- A person who disagrees to contraception during a clinical trial period.
- Patients with a history of malignancy within 5 years prior to the screening visit.
- Patients that other researchers are determined inadequately.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Nicotinamide(Mitovita)
Group2 Baseline-6week: (Mitovita: 1.0 g/day, QD) 6-12week: (Mitovita: 2.0 g/day, BID) Crossover 12-18week: (Placebo: 1.0 g/day, QD) 18-24week: (Placebo: 2.0 g/day, BID)
|
Nicotinamide(VitaminB3)
|
|
Placebo Comparator: Placebo
Group1 Baseline-6week: (Placebo: 1.0 g/day, QD) 6-12week: (Placebo: 2.0 g/day, BID) Crossover 12-18week: (Mitovita: 1.0 g/day, QD) 18-24week: (Mitovita: 2.0 g/day, BID)
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of PhNR_min(photopic negative response) as measured by Electroretinogram (intra-group)
Time Frame: Baseline,12weeks
|
Change of PhNR_min(photopic negative response) as measured by Electroretinogram after 12 weeks
|
Baseline,12weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of PhNR_min(photopic negative response) as measured by Electroretinogram (intra-group)
Time Frame: Baseline, 6, 12, 18, 24weeks
|
Change of PhNR_min(photopic negative response) as measured by Electroretinogram after 6, 12, 18 and 24 weeks
|
Baseline, 6, 12, 18, 24weeks
|
|
Change of PhNR_min(photopic negative response) as measured by Electroretinogram (Group1 VS Group2)
Time Frame: Baseline, 6, 12, 18, 24weeks
|
Change of PhNR_min(photopic negative response) as measured by Electroretinogram after 6, 12, 18 and 24 weeks
|
Baseline, 6, 12, 18, 24weeks
|
|
Change of mean deviation as measured by Visual Fields (intra-group)
Time Frame: Baseline, 12weeks, 24weeks
|
Change of mean deviation as measured by Visual Fields after 12 weeks and 24 weeks
|
Baseline, 12weeks, 24weeks
|
|
Change of mean deviation as measured by Visual Fields (Group1 VS Group2)
Time Frame: Baseline, 12weeks, 24weeks
|
Change of mean deviation as measured by Visual Fields after 12 weeks and 24 weeks
|
Baseline, 12weeks, 24weeks
|
|
Change of Pointwise sensitivity as measured by Visual Fields (Group1 VS Group2)
Time Frame: Baseline, 12weeks, 24weeks
|
Change of Pointwise sensitivity in glaucomatous eyes as measured by Visual Fields after 12 and 24 weeks: total/pattern deviation
|
Baseline, 12weeks, 24weeks
|
|
Change of visual field sensitivity number of locations
Time Frame: Baseline, 12weeks, 24weeks
|
Change of visual field sensitivity number of locations in glaucomatous eyes as measured by Visual Fields after 12 and 24 weeks: total, pattern deviation
|
Baseline, 12weeks, 24weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Seungsoo Rho, MD, PhD, CHA Bundang Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Eye Diseases
- Cysts
- Ocular Hypertension
- Connective Tissue Diseases
- Mucinoses
- Glaucoma
- Ganglion Cysts
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Antimetabolites
- Micronutrients
- Hypolipidemic Agents
- Lipid Regulating Agents
- Vitamins
- Vitamin B Complex
- Nicotinic Acids
- Niacinamide
- Niacin
Other Study ID Numbers
Other Study ID Numbers
- NRG1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.